Here are the 424B prospectus supplements from Ocugen, Inc. (OCGN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow OCGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OCGN filings page.
Ocugen, Inc. is offering 15,000,000 shares of common stock at $1.50 per share, for gross proceeds of $22.5 million and estimated net proceeds of about $20.85 million. The company expects to use the cash for general corporate purposes, including working capital, capital expenditures, and administrative costs, and may also invest in complementary businesses or technologies.
Shares outstanding will rise from 312,319,623 as of September 30, 2025 to 327,888,374, creating immediate dilution of $1.43 per share for new investors based on an as adjusted net tangible book value of $0.07. Ocugen highlights ongoing losses, substantial doubt about its ability to continue as a going concern without additional funding, and the likelihood of further capital raises. The filing also describes late-stage gene therapy programs, including OCU410 and OCU400, with recent positive clinical data in retinal diseases.